Nat. Biotechnol. 23, 645–647 (2005)

On page 646, Table 1, last column, the status of the Osel bacteriotherapy Clostridium butyricum was given as “Phase 2 trial.” It should have read, “Phase 2/3 trial (US) planned.”

On page 647, column 2, last paragraph, line 16, “...a tumor marker present in many ovarian and prostate cancers...” should have read “a tumor marker present in many ovarian and pancreatic cancers....” Prostate cancers should have been pancreatic cancers. In the last line of the same paragraph, “EphsA2 antigen” should have been “EphA2 antigen.”